How a Google DeepMind Spinoff Hunts Hidden Drug Targets

The more telling detail isn't the funding size but who is paying: Novartis and Eli Lilly are writing checks to a competitor's spinout rather than building equivalent capability in-house, which is a quiet admission that internal AI drug discovery efforts at major pharma aren't keeping pace.

The recent coverage of OpenAI and Anthropic's API price war (The Decoder, June 11) illustrates a pattern playing out one layer up the stack: once foundational capabilities commoditize, competition shifts to applied differentiation and pricing power. Isomorphic is betting that molecular optimization, not structure prediction, is where defensible margin lives in biotech AI, roughly the same logic that separates inference providers from application-layer winners in the LLM space. The pharma partnerships function less like R&D collaborations and more like early lock-in agreements, buying Isomorphic time to prove the Drug Design Engine before well-capitalized rivals close the gap.

Watch whether either Novartis or Eli Lilly announces a candidate that entered preclinical trials through the Drug Design Engine within the next 18 months. A named candidate would validate the pipeline compression claim; continued silence would suggest the partnerships are still exploratory rather than productive.